In this strategic cooperation Bayn’s innovation and formula development enters into industrialisation of tablet and lozenges and provides the market with a total solution. Doing this shortens the lab to market process, giving Bayn a great opportunity to generate new revenue faster.

“We are very pleased about this cooperation which enables Bayn to industrialise and produce our formulas of tablets and lozenges for the market and to generate revenue. The cooperation provides opportunities for finished products which can directly serve the market with the highest quality standard and competitive advantages in this product area around the world”, says Lucy Dahlgren, CEO at Bayn.

“Bayn is a specialist in natural sweetening solutions and sensory analysis. We are delighted to work with Bayn’s specialist in the new formula and product development. This cooperation will create business value for both of us”, says Lars Jern, CEO at Jemedic.